成人鼻用糖皮质激素安全性与不良事件的系统评价与Meta分析
该系统评价与Meta分析纳入60项研究,评估FDA批准及非批准鼻用糖皮质激素在成人中的安全性。结果显示总体安全,但Meta分析显示FDA批准组鼻出血风险显著高于对照(RR 1.56;95%CI 1.13-2.14;
要点
- 成人使用鼻用糖皮质激素总体安全,无皮质醇或眼压持续异常。
- 非标准用法的安全性结论仅限文献报告的给药方式和剂量。
核心结论
- 成人使用FDA批准及文献报道的非FDA批准鼻用糖皮质激素总体安全。
- 与安慰剂相比,鼻用糖皮质激素组鼻出血风险增加,其余不良事件无显著差异。
研究设计与样本
- 系统评价与Meta分析,遵循PRISMA指南,检索MEDLINE、PubMed和EMBASE数据库。
- 共纳入60项研究,涵盖鼻喷剂、滴剂、注射剂、气雾剂和冲洗等多种剂型。
- 采用牛津循证医学中心标准对每项研究进行证据等级分级。
主要发现
- 未发现皮质醇水平或眼压的持续异常。
- 其余不良事件在治疗组与安慰剂组间无显著差异。
临床怎么用
- 成人使用鼻用糖皮质激素时需关注鼻出血风险,尤其是FDA批准剂型。
- 非标准给药方式的安全性解读应限于文献报道的给药方法和剂量。
局限性
- 非标准鼻用糖皮质激素的安全性结论仅基于文献中报道的给药方式和剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To address concerns related to the safety profile of both Food and Drug Administration (FDA)-approved and non-FDA-approved intranasal corticosteroid (INCS) use in the adult population. DATA SOURCE: Systematic review of MEDLINE, PubMed, and EMBASE databases using a comprehensive search strategy including all INCS formulations and adverse events. The study design was developed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Additional sources were identified from study references of relevant articles. REVIEW METHODS: A structured literature search was conducted. Each study was graded for level of evidence using the Oxford Centre for Evidence-Based Medicine. Extracted data included population size, study design, drug (dosage, route, and frequency), presence of hypothalamus pituitary axis suppression, ocular symptoms, and treatment-related adverse events. RESULTS: A total of 60 studies met inclusion criteria. The studies included use of INCS as metered nasal sprays, drops, injections, aerosols, and irrigations. There were no persistent abnormalities in cortisol level or intraocular pressure change. Meta-analysis of epistaxis showed a significantly increased risk in the FDA-approved treatment group in comparison with control (risk ratio 1.56; 95% confidence interval, 1.13-2.14; P = .007). CONCLUSIONS: Overall, it appears that the use of both FDA and published non-FDA application of INCS are safe in the adult population. Meta-analysis demonstrated an increased risk of epistaxis in patients using INCS compared with placebo. Otherwise, there was no significant difference between in adults in the treatment group and placebo group. As an important caveat, the interpretation of safety of nonstandard INCS is restricted to delivery methods and dosages published in the literature.
引用
- Donaldson AM, Choby G, Kim DH, et al. Intranasal Corticosteroid Therapy: Systematic Review and Meta-analysis of Reported Safety and Adverse Effects in Adults. Otolaryngol Head Neck Surg. 2020. PMID: 32539494. doi:10.1177/0194599820931455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。